Literature DB >> 23583432

Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study.

Siew C Ng1, Whitney Tang2, Jessica Y Ching2, May Wong2, Chung Mo Chow3, A J Hui4, T C Wong5, Vincent K Leung6, Steve W Tsang7, Hon Ho Yu8, Mo Fong Li8, Ka Kei Ng9, Michael A Kamm10, Corrie Studd10, Sally Bell10, Rupert Leong11, H Janaka de Silva12, Anuradhani Kasturiratne12, M N F Mufeena12, Khoon Lin Ling13, Choon Jin Ooi13, Poh Seng Tan14, David Ong14, Khean L Goh15, Ida Hilmi15, Pises Pisespongsa16, Sathaporn Manatsathit17, Rungsun Rerknimitr18, Satimai Aniwan18, Yu Fang Wang19, Qin Ouyang19, Zhirong Zeng20, Zhenhua Zhu20, Min Hu Chen20, Pin Jin Hu20, Kaichun Wu21, Xin Wang21, Marcellus Simadibrata22, Murdani Abdullah22, Justin Cy Wu2, Joseph J Y Sung2, Francis K L Chan2.   

Abstract

BACKGROUND & AIMS: Inflammatory bowel diseases (IBD) are becoming more common in Asia, but epidemiologic data are lacking. The Asia-Pacific Crohn's and Colitis Epidemiology Study aimed to determine the incidence and phenotype of IBD in 8 countries across Asia and in Australia.
METHODS: We performed a prospective, population-based study of IBD incidence in predefined catchment areas, collecting data for 1 year, starting on April 1, 2011. New cases were ascertained from multiple overlapping sources and entered into a Web-based database. Cases were confirmed using standard criteria. Local endoscopy, pathology, and pharmacy records were searched to ensure completeness of case capture.
RESULTS: We identified 419 new cases of IBD (232 of ulcerative colitis [UC], 166 of Crohn's disease [CD], and 21 IBD-undetermined). The crude annual overall incidence values per 100,000 individuals were 1.37 for IBD in Asia (95% confidence interval: 1.25-1.51; 0.76 for UC, 0.54 for CD, and 0.07 for IBD-undetermined) and 23.67 in Australia (95% confidence interval: 18.46-29.85; 7.33 for UC, 14.00 for CD, and 2.33 for IBD-undetermined). China had the highest incidence of IBD in Asia (3.44 per 100,000 individuals). The ratios of UC to CD were 2.0 in Asia and 0.5 in Australia. Median time from symptom onset to diagnosis was 5.5 months (interquartile range, 1.4-15 months). Complicated CD (stricturing, penetrating, or perianal disease) was more common in Asia than Australia (52% vs 24%; P = .001), and a family history of IBD was less common in Asia (3% vs 17%; P < .001).
CONCLUSIONS: We performed a large-scale population-based study and found that although the incidence of IBD varies throughout Asia, it is still lower than in the West. IBD can be as severe or more severe in Asia than in the West. The emergence of IBD in Asia will result in the need for specific health care resources, and offers a unique opportunity to study etiologic factors in developing nations.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23583432     DOI: 10.1053/j.gastro.2013.04.007

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  270 in total

1.  Impact of Obesity on the Management of Inflammatory Bowel Disease.

Authors:  Amanda M Johnson; Edward V Loftus
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-07

Review 2.  The global burden of IBD: from 2015 to 2025.

Authors:  Gilaad G Kaplan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-09-01       Impact factor: 46.802

Review 3.  The epidemiology and risk factors of inflammatory bowel disease.

Authors:  Yulan Ye; Zhi Pang; Weichang Chen; Songwen Ju; Chunli Zhou
Journal:  Int J Clin Exp Med       Date:  2015-12-15

4.  The Trend of Inflammatory Bowel Diseases in Taiwan: A Population-Based Study.

Authors:  Chia-Jung Kuo; Kuang-Hui Yu; Lai-Chu See; Cheng-Tang Chiu; Ming-Yao Su; Chen-Ming Hsu; Chang-Fu Kuo; Meng-Jiun Chiou; Jia-Rou Liu; Hung-Wei Wang
Journal:  Dig Dis Sci       Date:  2015-04-03       Impact factor: 3.199

5.  Correlation between triggering receptor expressed on myeloid cells-1 and clinical disease activity in Chinese patients with ulcerative colitis.

Authors:  Shulan Zhang; Jing Luo; Bingbing Shen; Lijun Li; Chaojun Hu; Ping Li; Chuiwen Deng; Fengchun Zhang; Jiaming Qian; Yongzhe Li
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 6.  The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications.

Authors:  Jason R Goldsmith; R Balfour Sartor
Journal:  J Gastroenterol       Date:  2014-03-21       Impact factor: 7.527

Review 7.  From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease.

Authors:  Charles W Randall; John A Vizuete; Nicholas Martinez; John J Alvarez; Karthik V Garapati; Mazyar Malakouti; Carlo M Taboada
Journal:  Therap Adv Gastroenterol       Date:  2015-05       Impact factor: 4.409

Review 8.  Enteric bacterial proteases in inflammatory bowel disease- pathophysiology and clinical implications.

Authors:  Ian M Carroll; Nitsan Maharshak
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

Review 9.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

10.  Association of Vitamin D Level With Clinical Status in Inflammatory Bowel Disease: A 5-Year Longitudinal Study.

Authors:  Toufic A Kabbani; Ioannis E Koutroubakis; Robert E Schoen; Claudia Ramos-Rivers; Nilesh Shah; Jason Swoger; Miguel Regueiro; Arthur Barrie; Marc Schwartz; Jana G Hashash; Leonard Baidoo; Michael A Dunn; David G Binion
Journal:  Am J Gastroenterol       Date:  2016-03-08       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.